AP&T: 血清生长分化因子15可以预测丙型肝炎患者病毒消除后肝细胞癌的发生

2022-02-12 MedSci原创 MedSci原创

丙型肝炎一般指丙型病毒性肝炎。 丙型病毒性肝炎,简称为丙型肝炎、丙肝,是一种由丙型肝炎病毒(HCV)感染引起的病毒性肝炎,主要经输血、针刺、吸毒等传播。

      直接作用抗病毒药物(DAAs)的问世直接导致了丙型肝炎治疗方式的改变,几乎所有的慢性丙型肝炎(CH-C)患者都可以通过DAAs完全治愈。一项大型的队列分析表明,丙型肝炎病毒的消除与肝病风险的降低有关。然而,在抗病毒治疗后,即使丙型肝炎病毒(HCV)被清除,肝癌(HCC)也可能发生。因此,临床上迫切需要预测DAA治疗后HCC发生的生物标志物。生长分化因子15(GDF15)是一种细胞因子,其表达量在氧化应激和线粒体应激下会明显增加。在肝脏纤维化和HCC的发病机制中,HCV感染的肝细胞对氧化应激反应敏感。因此,血清中的GDF15水平反映了肝脏的炎症环境,并有助于肿瘤细胞的增殖。本项研究旨在评估 GDF15 对消除 HCV 后发生 HCC 的预后价值。

 

      为了完成本项研究,研究人员检测了没有 HCC 病史的慢性 HCV 感染患者的血清中的 GDF15 水平,所有纳入的患者均使用直接作用抗病毒药物 (DAA) 获得了持续的病毒学应答。

 

       在模型构建队列中,DAA 治疗后发生 HCC 的患者的血清 GDF15 水平高于未治疗的患者。多变量 Cox 比例风险分析显示基线 GDF15 (>1350 pg/mL, HR 2.54)、AFP (>5 ng/mL, HR 2.00) 和 FIB-4 指数 (>3.25, HR 2.69) 是肝癌发生的独立危险因素。在模型验证队列中,低分 (N = 171)、中分 (N = 300) 和高分 (N = 166) 组的 3 年累积 HCC 发生率分别为 0.64%、3.27% 和 15.3%。在整个队列中,评分将 FIB-4 指数≤3.25(3 年 HCC 发生率为 2.0%)的患者分为中等评分组和低评分组。

图:血清生长分化因子15可以预测丙型肝炎

 

      通过本项研究,研究人员证实血清GDF15水平可预测新发HCC 的发生概率,使用 GDF15、AFP 和 FIB-4 指数进行组合评分可以预测HCV 消除后发生生 HCC 的风险。

 

 

原始出处:

Yuta Myojin. Et al. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.Alimentary Pharmacology & Therapeutics.2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1979292, encodeId=034119e92929e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Nov 03 22:09:07 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655016, encodeId=f030165501655, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Sat Jun 11 21:09:07 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807928, encodeId=8ad1180e92818, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Nov 04 00:09:07 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193838, encodeId=de03119383836, content=加分不, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Wed Feb 16 00:05:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863651, encodeId=e79d18636515a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 25 21:09:07 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274701, encodeId=d27812e4701f4, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Feb 14 11:09:07 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1979292, encodeId=034119e92929e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Nov 03 22:09:07 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655016, encodeId=f030165501655, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Sat Jun 11 21:09:07 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807928, encodeId=8ad1180e92818, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Nov 04 00:09:07 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193838, encodeId=de03119383836, content=加分不, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Wed Feb 16 00:05:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863651, encodeId=e79d18636515a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 25 21:09:07 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274701, encodeId=d27812e4701f4, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Feb 14 11:09:07 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1979292, encodeId=034119e92929e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Nov 03 22:09:07 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655016, encodeId=f030165501655, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Sat Jun 11 21:09:07 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807928, encodeId=8ad1180e92818, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Nov 04 00:09:07 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193838, encodeId=de03119383836, content=加分不, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Wed Feb 16 00:05:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863651, encodeId=e79d18636515a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 25 21:09:07 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274701, encodeId=d27812e4701f4, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Feb 14 11:09:07 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1979292, encodeId=034119e92929e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Nov 03 22:09:07 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655016, encodeId=f030165501655, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Sat Jun 11 21:09:07 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807928, encodeId=8ad1180e92818, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Nov 04 00:09:07 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193838, encodeId=de03119383836, content=加分不, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Wed Feb 16 00:05:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863651, encodeId=e79d18636515a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 25 21:09:07 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274701, encodeId=d27812e4701f4, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Feb 14 11:09:07 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
    2022-02-16 我不是针对谁

    加分不

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1979292, encodeId=034119e92929e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Nov 03 22:09:07 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655016, encodeId=f030165501655, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Sat Jun 11 21:09:07 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807928, encodeId=8ad1180e92818, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Nov 04 00:09:07 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193838, encodeId=de03119383836, content=加分不, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Wed Feb 16 00:05:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863651, encodeId=e79d18636515a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 25 21:09:07 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274701, encodeId=d27812e4701f4, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Feb 14 11:09:07 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
    2022-05-25 xjy02
  6. [GetPortalCommentsPageByObjectIdResponse(id=1979292, encodeId=034119e92929e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Nov 03 22:09:07 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655016, encodeId=f030165501655, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Sat Jun 11 21:09:07 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807928, encodeId=8ad1180e92818, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Nov 04 00:09:07 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193838, encodeId=de03119383836, content=加分不, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Wed Feb 16 00:05:53 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863651, encodeId=e79d18636515a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed May 25 21:09:07 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274701, encodeId=d27812e4701f4, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Feb 14 11:09:07 CST 2022, time=2022-02-14, status=1, ipAttribution=)]

相关资讯

诺奖得主背后的“无名英雄”

10月5日,诺贝尔生理学或医学奖花落Harvey James Alter、Michael Houghton和Charles M. Rice这三位科学家,以表彰他们在丙肝病毒(HCV)发现史上的卓越成就

Gut:肝癌治疗后抗丙肝病毒治疗可预防肝癌复发吗?

肝癌治疗后抗丙肝病毒治疗可预防肝癌复发吗?

JCLA:迈瑞(mindray)抗丙肝病毒检测方法检测丙型肝炎病毒感染的效果评价

目前,丙型肝炎病毒(HCV)抗体检测用于丙型肝炎病毒感染筛查。在中国,最近启动了基于第三代免疫测定法的迈瑞抗丙肝病毒试验。本研究的目的是评价其与其他两种广泛使用的化验的诊断性能。 研究人员采用6个丙肝病毒感染血清转化板评价该方法的早期检测敏感性。采用迈瑞抗HCV、伊莱西抗HCV II和Architect抗HCV试验检测共1952个临床样本。使用至少一种抗丙肝病毒试验得到反应结果的样本,用重组

AJKD:在透析人群中消除肝炎病毒——一种新型的合作护理模式

血液透析设施是丙型肝炎病毒(HCV)传播的高危环境,分子病毒学技术已经明确表明,

透析间里的“沉默杀手”—— 丙肝病毒

丙型肝炎病毒(HCV)从被发现到被治愈,都映证了人类的智慧: HCV是医学史上第一次单纯依赖分子生物学手段(噬菌体展示技术)被鉴定的病毒,HCV是第一个被“直接抗病毒药物”(DAA)攻克的病毒,DAA时代,丙肝迅速变成了一种可以轻松治愈的疾病,HCV基础研究几无价值,临床研究也渐渐式微,但现实世界的严峻又与研究领域的寂寥形成鲜明对比——。

2018 AASLD/IDSA建议:丙肝病毒感染的检测,管理和治疗(更新版)

意识到及时控制丙肝感染快速发展的重要性,美国肝病研究学会(AASLD)以及美国感染病学会(IDSA)制定了丙肝病毒感染的检测,管理和治疗建议指南,并于2014年推出。本文是对该指南的更新,主要内容涉及丙肝的初始治疗,再治疗以及特殊人群的管理。